Resonative is administered intramuscularly.Before the introduction of the ampoule with the drug should be brought to room temperature or body temperature. The drug is not intended for intravenous administration (the risk of anaphylactic shock). It should be administered only intramuscularly. To do this, after inserting the needle into the muscle, you need to feed the syringe piston slightly back to make sure there is no blood in the needle. In case of erroneous intravenous administration, the duration of observation of the patient should be at least 1 hour.
If it is necessary to introduce a large volume of the drug (more than 5 ml), the dose should be divided into several parts administered separately, to different injection zones.
When hemorrhagic disorders, when intramuscular injections are contraindicated, the drug can be injected subcutaneously. Place the injection should be gently massaged and put a compress.
The dose of immunoglobulin anti- Rho(D) is determined in accordance with the amount of Rh positive fetal red blood cells that have entered the mother's bloodstream. Calculation of the dose is based on the fact that 0.5 ml of Rhesus positive red blood cells or 1 ml of Rh-positive blood is neutralized approximately 50 ME (10 μg) of the immunoglobulin anti-D.
When prenatal care once injected 1250 ME (250 mcg) of the drug at the 28th-30th week of pregnancy; or injected at 1250 ME (250 mcg) twice - at the 28th and 34th weeks of pregnancy.
When postpartum prophylaxis the drug is administered once in a dose of 1250 ME (250 μg) as quickly as possible within 72 hours after delivery. If after the delivery more than 72 hours have passed, do not give up the drug, and enter it as soon as possible. The drug must be administered after delivery, despite its use in the prenatal period, and also, despite the presence of residual antirezus antibodies in the mother serum.
When prevention in the case of various complications of pregnancy and childbirth the drug is administered once - in a dose of 625 ME (125 mcg) with a gestation period of up to 12 weeks or at a dose of 1250 ME (250 mcg) after the 12th week of pregnancy. The drug should be administered as soon as possible within 72 hours. If necessary, the drug should be repeated every 6-12 weeks throughout the pregnancy.
After amniocentesis and chorionic biopsy once injected 1250 ME (250 μg) of the drug.
If it is suspected that fetomaternal bleeding is more than 4 ml (in case of fetal / newborn or fetal death),it is necessary to estimate its value by an appropriate method, for example, by the acid leaching method by Kleichauer-Bethke, which determines fetal hemoglobin, or by the method of stream cytometry, which identifies Rh-positive red blood cells. The additional dose of Resonative is calculated in accordance with the ratio 100 ME (20 μg) of the preparation per 1.0 ml of fetal erythrocytes.
When Rhesus-incompatible blood transfusions the recommended dose is 100 ME (20 μg) of the immunoglobulin anti-Rho(D) in 2 ml of Rh-positive blood or 1 ml of erythrocyte mass. To determine the dose, it is advisable to consult a transfusiologist.
Every 48 hours, the presence of Rh-positive erythrocytes in the recipient should be monitored and the need for an additional dose of immunoglobulin anti-Rho(D) until their complete elimination.
In the case of transfusion of large quantities of incompatible blood or erythrocyte mass, a maximum dose of 15,000 ME (3 000 μg) of the drug, despite the fact that the volume of transfused Rhesus-positive red blood cells could be more than 300 ml. Large doses of the drug should be administered within a few days.